

Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis

AMIMI S. OSAYANDE, MD, FAAFP, *Gwinnett Medical Center, Lawrenceville, Georgia*

NEELIMA KALE, PhD, MD, FAAFP, *University of Texas Southwestern Medical Center, Dallas, Texas*

This guide is one in a series that offers evidence-based tools to assist family physicians in improving their decision-making at the point of care.

This series is coordinated by Mark H. Ebell, MD, MS, Deputy Editor for Evidence-Based Medicine.

A collection of Point-of-Care Guides published in *AFP* is available at <http://www.aafp.org/afp/poc>.

CME This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz on page 764. Author disclosure: No relevant financial affiliations.

Clinical Question

Which patients with nonalcoholic fatty liver disease (NAFLD) have a low likelihood of fibrosis or cirrhosis?

Evidence Summary

NAFLD is defined as hepatic steatosis on imaging or histology in the absence of other etiologies for secondary fat accumulation. It is usually identified during the evaluation of elevated transaminase levels in a patient without heavy alcohol intake, or found incidentally on imaging studies. The estimated median prevalence in the general population is 20% worldwide,¹ and is an estimated 10% to 35% in the United States.² Nonalcoholic steatohepatitis is a subset of NAFLD characterized by hepatic inflammation and evidence of hepatocyte injury with or without fibrosis, and is associated with an increased risk of cirrhosis and hepatocellular carcinoma.² The prevalence of biopsy-proven nonalcoholic steatohepatitis in U.S. patients with NAFLD is about 3% to 5%.²

Although liver biopsy remains the standard test for diagnosing fibrosis, it is invasive with significant associated risks. Therefore, a noninvasive method for identifying those at low risk of fibrosis in whom liver biopsy can be avoided would be useful.


Several noninvasive scoring systems using readily available parameters have been proposed to identify advanced fibrosis in patients with NAFLD. These include the aspartate transferase to platelet ratio index³; the alanine transferase ratio⁴; and the BARD score,⁵ which comprises the weighted sum of three variables (body mass index [BMI] of 28 kg per m² or more, aspartate transferase to alanine transferase ratio, and the presence of diabetes mellitus). The FIB-4 score has similar variables

as the aspartate transferase to platelet ratio index, with the addition of age.⁶ Finally, the NAFLD fibrosis score includes age, BMI, blood glucose levels, transferase levels, platelet count, and albumin levels.⁷ It identifies low-, moderate-, and high-risk groups. However, there is no good prospective evidence that identifying and evaluating high-risk groups with liver biopsy leads to improved health outcomes.

Pooled data from a meta-analysis of 13 studies with 3,064 patients compared the diagnostic accuracy of noninvasive clinical scoring systems using liver biopsy as a reference standard.⁸ Three scoring systems were evaluated: NAFLD fibrosis score; BARD score; and transient elastography (Fibroscan), an ultrasound-based technique that uses measured liver stiffness to estimate fibrosis.⁹ The NAFLD fibrosis score was the best scoring system to predict fibrosis with regards to ease of use, cost, and independent validation across various populations. The low-risk group has a negative likelihood ratio (LR⁻) of 0.17 for advanced fibrosis (stage 3 or more on the annual fibrosis progression rate), whereas the high-risk group has a positive likelihood ratio (LR⁺) of 20.3 for advanced fibrosis.

A systematic review of nine studies with 3,425 patients found summary estimates for sensitivity and specificity of 90% and 97%, respectively, and an area under the receiver operating characteristic curve (AUROC) of 0.85 for the NAFLD fibrosis score.¹⁰ A 2016 meta-analysis of four studies with 1,038 patients compared the FIB-4 score, NAFLD fibrosis score, and BARD score.¹¹ The FIB-4 score with a low cutoff of 1.3 had better diagnostic accuracy for advanced fibrosis than the other scoring systems, using pooled summary

Evaluating NAFLD in Primary Care



*—The NAFLD fibrosis score is available as an online calculator at <http://www.naflscore.com>, or it can be calculated using the following equation: $-1.675 + 0.037 \times \text{age (year)} + 0.094 \times \text{BMI (kg per m}^2) + 1.13 \times \text{impaired fasting glucose/diabetes mellitus (yes = 1, no = 0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet count (} \times 10^9 \text{ per L)} - 0.66 \times \text{albumin (g per dL)}$.

†—Additional tests such as transient elastography (Fibroscan) and fibrosis biomarker measurements may be useful to further stratify patients with an indeterminate NAFLD fibrosis score.

Figure 1. Evaluating NAFLD in primary care. (ALT = alanine transferase; AST = aspartate transferase; BMI = body mass index; NAFLD = nonalcoholic fatty liver disease.)

Information from reference 8.

receiver operating curves. The AUROC was 0.85; however, this finding was of limited value because of a low specificity of 0.69 and a low LR+ of 2.95. In the same study, pooled data regarding the NAFLD fibrosis score had an AUROC of 0.84 for the lower cutoff, with an LR+ of 3.1 and LR− of 0.32. For the high cutoff of 0.68, the AUROC was lower at 0.65; however, the LR+ of 11.6 was very good.

The FIB-4 score and NAFLD fibrosis score are recommended for identifying patients at risk of fibrosis. The NAFLD fibrosis score has the benefit of a good negative predictive value for excluding fibrosis, an important consideration. The NAFLD fibrosis score has also been the most extensively validated tool for identifying those with advanced disease. The American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology recommend its use for determining the need for liver biopsy.¹ The score is also available as a free online calculator at <http://www.naflscore.com>.

Patients with an NAFLD fibrosis score less than the low cutoff can reliably be considered at low risk of

fibrosis and can be managed by their primary care physicians (Figure 1⁸). Patients with an indeterminate or high risk using the high cutoff warrant further investigation, including fibrosis biomarker identification, imaging, and possible referral for liver biopsy.¹⁰

Applying the Evidence

A 56-year-old woman with a BMI of 32 kg per m² has a mild elevation of transaminase levels on routine screening. Her aspartate transferase level is 83 U per L (1.39 μ kat per L), normal = 10 to 40 U per L (0.17 to 0.67 μ kat per L); and alanine transferase is 100 U per L (1.67 μ kat per L), normal = 7 to 56 U per L (0.12 to 0.94 μ kat per L). Other pertinent laboratory findings include a serum albumin level of 4.4 g per dL (44 g per L), normal = 3.5 to 5.5 g per dL (35 to 55 g per L); and a normal complete blood count, with a platelet count of 230×10^3 per mm³ (230×10^9 per L). Ultrasonography shows fatty infiltration of the liver. She does not have impaired glucose tolerance, and she does not drink alcohol. How should this patient be managed?

Answer: Using the online calculator (<http://www.naflscore.com>), she has an NAFLD fibrosis score of −1.667, which is less than the low cutoff of −1.455. Thus, the probability that she has significant fibrosis is low, and she can be treated by her primary care physician.

Address correspondence to Amimi S. Osayande, MD, at aosayande@gwinnettmedicalcenter.org. Reprints are not available from the authors.

REFERENCES

- Chalasan N, et al. The diagnosis and management of non-alcoholic fatty liver disease [published correction appears in *Gastroenterology*. 2012;143(2):503]. *Gastroenterology*. 2012;142(7):1592-1609.
- Vernon G, Baranova A, Younossi ZM. The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34(3):274-285.
- Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. 2003;38(2):518-526.
- Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. *Gastroenterology*. 1988;95(3):734-739.
- Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut*. 2008;57(10):1441-1447.
- Vallet-Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. *Hepatology*. 2007;46(1):32-36.
- Angulo P, et al. The NAFLD fibrosis score. *Hepatology*. 2007;45(4):846-854.
- Musso G, Gambino R, Cassader M, Pagano G. Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med*. 2011;43(8):617-649.
- Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography. *Ultrasound Med Biol*. 2003;29(12):1705-1713.
- Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2011;33(5):525-540.
- Sun W, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease. *Hepatal Res*. 2016;46(9):862-870. ■